BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 37240281)

  • 1. Regulation of the Cell Cycle by ncRNAs Affects the Efficiency of CDK4/6 Inhibition.
    Hu Q; Huang T
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15.
    Iavarone A; Massagué J
    Nature; 1997 May; 387(6631):417-22. PubMed ID: 9163429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of cyclin-dependent kinase 4 during adipogenesis involves switching of cyclin D subunits and concurrent binding of p18INK4c and p27Kip1.
    Phelps DE; Xiong Y
    Cell Growth Differ; 1998 Aug; 9(8):595-610. PubMed ID: 9716177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D-CDK4/6 functions in cancer.
    Gao X; Leone GW; Wang H
    Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
    Reynisdóttir I; Polyak K; Iavarone A; Massagué J
    Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule cyclin-dependent kinase inhibitors protect against neuronal cell death in the ischemic-reperfused rat retina.
    Sakamoto K; Ohki K; Saito M; Nakahara T; Ishii K
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):419-25. PubMed ID: 21714634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell antigen receptor-mediated activation of cyclin-dependent retinoblastoma protein kinases and inhibition by co-cross-linking with Fc gamma receptors.
    Tanguay D; Pavlovic S; Piatelli MJ; Bartek J; Chiles TC
    J Immunol; 1999 Sep; 163(6):3160-8. PubMed ID: 10477583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecules inducing specific cyclin-dependent kinase degradation and their possible use in cancer therapy.
    Zheng M; Zhang XY; Chen W; Xia F; Yang H; Yuan K; Yang P
    Future Med Chem; 2024 Feb; 16(4):369-388. PubMed ID: 38288571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
    Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
    Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
    Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip).
    Chen WJ; Chang CY; Lin JK
    Biochem Pharmacol; 2003 Jun; 65(11):1777-85. PubMed ID: 12781329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
    Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
    Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes.
    McConnell BB; Gregory FJ; Stott FJ; Hara E; Peters G
    Mol Cell Biol; 1999 Mar; 19(3):1981-9. PubMed ID: 10022885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells.
    Sandhu C; Garbe J; Bhattacharya N; Daksis J; Pan CH; Yaswen P; Koh J; Slingerland JM; Stampfer MR
    Mol Cell Biol; 1997 May; 17(5):2458-67. PubMed ID: 9111314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinoic acid-mediated growth arrest of EBV-immortalized B lymphocytes is associated with multiple changes in G1 regulatory proteins: p27Kip1 up-regulation is a relevant early event.
    Zancai P; Cariati R; Rizzo S; Boiocchi M; Dolcetti R
    Oncogene; 1998 Oct; 17(14):1827-36. PubMed ID: 9778049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1.
    Nguyen MD; Boudreau M; Kriz J; Couillard-Després S; Kaplan DR; Julien JP
    J Neurosci; 2003 Mar; 23(6):2131-40. PubMed ID: 12657672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
    Klein MA
    Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.